Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | RYR2 | Q92736 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL373746 | 0.88 | USP2 (0.46) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL6485137 | 0.80 | KDM4E (0.43) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL16028605 | 0.80 | KDM4E (0.43) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL6481562 | 0.78 | KDM4E (0.41) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL4285974 | 0.77 | GPR119 (0.43) | USP2 | |
| SCHEMBL4073156 | 0.74 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| Busulfan SCHEMBL4373 | 0.72 | TSHR (1.00) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| Busulfan SCHEMBL4764696 | 0.72 | TSHR (1.00) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL576408 | 0.72 | TSHR (0.88) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL16845884 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2532657-B9 | Compounds and methods of use | SUNSHINE LAKE PHARMA CO LTD (CN) | 2017-04-19 | — | — | EP | disclosed |
| EP-2532657-B1 | Compounds and methods of use | SUNSHINE LAKE PHARMA CO LTD (CN) | 2016-08-31 | — | — | EP | disclosed |
| EP-2408300-B1 | AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2016-05-11 | — | — | EP | disclosed |
| US-8426585-B2 | Compounds comprising a spiro-ring | Xi, Ning (US) | 2013-04-23 | — | — | US | disclosed |
| US-20120315247-A1 | COMPOUNDS COMPRISING A SPIRO-RING AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2012-12-13 | — | — | US | disclosed |
| EP-2532657-A2 | Compounds and methods of use | Sunshine Lake Pharma Co., Ltd (CN) | 2012-12-12 | — | — | EP | disclosed |
| US-8293897-B2 | Compounds comprising a spiro-ring and methods of use | Xi, Ning (US) | 2012-10-23 | — | — | US | disclosed |
| US-8232294-B2 | Amino ester derivatives, sailts thereof and methods of use | Xi, Ning (US) | 2012-07-31 | — | — | US | disclosed |
| EP-2408300-A1 | AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE | Sunshine Lake Pharma Co., Ltd (CN) | 2012-01-25 | — | — | EP | disclosed |
| EP-2340244-A1 | COMPOUNDS AND METHODS OF USE | Xi, Ning (US) | 2011-07-06 | — | — | EP | disclosed |
| WO-2010111063-A1 | AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE | XI NING (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20100239576-A1 | AMINO ESTER DERIVATIVES, SAILTS THEREOF AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| WO-2010045095-A1 | COMPOUNDS AND METHODS OF USE | XI NING (US) | 2010-04-22 | — | — | WO | disclosed |
| US-20100093727-A1 | COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239576-A1 | AMINO ESTER DERIVATIVES, SAILTS THEREOF AND METHODS OF USE | SRC, BCAT1, BCAT2 | KDM4E 806/4885USP2 1326/4885ALDH1A1 2796/4885 |
| US-20100093727-A1 | COMPOUNDS AND METHODS OF USE | PRKDC, PRKACA, PRKX | KDM4E 2384/4885USP2 1386/4885ALDH1A1 3826/4885 |
| US-20120315247-A1 | COMPOUNDS COMPRISING A SPIRO-RING AND METHODS OF USE | CDC42BPG, HRAS, PTPRJ | KDM4E 3389/4885USP2 3296/4885ALDH1A1 2232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.